US dispute with Pharma giant over quality control
Source: The Times
Date: 18/03/2005
The US Food and Drug Administration yesterday signalled that a dispute over
manufacturing quality at GlaxoSmithKline could result in a fine and tough new
compliance requirements. The FDA has been heading for a showdown with Glaxo
over quality control issues at its Cidra factory since 2002, where investigators
were unhappy with the manufacture of Paxil and Avandamet.
<<< Back to main page
